Trial Profile
The Healthy Volunteer Evaluation of an Aptamer-RNA Target to Factor IXa
Status:
Completed
Phase of Trial:
Phase I
Latest Information Update: 10 Nov 2021
Price :
$35
*
At a glance
- Drugs Anivamersen-pegnivacogin (Primary) ; Anivamersen; Pegnivacogin
- Indications Acute coronary syndromes; Venous thrombosis
- Focus Adverse reactions; Pharmacodynamics; Pharmacokinetics
- 03 Sep 2008 Results have been published in the proceedings of the ESC Congress 2008: Annual Congress of the European Society of Cardiology.
- 12 Nov 2007 New trial record.